Phase 1b Study of Venetoclax with Decitabine or Azacitidine for Elderly Patients with Untreated AML


Phase 1b Study of Venetoclax with Decitabine or Azacitidine for Elderly Patients with Untreated AML
Slides from a presentation at ASH 2015 and transcribed comments from a recent interview with Richard M Stone, MD (2/16/16)

DiNardo C et al. A Phase 1b study of venetoclax (ABT-199/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are ≥ to 65 years and not eligible for standard induction therapy. Proc ASH 2015;Abstract 327.

Dr Stone is Director of the Adult Leukemia Program at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School in Boston, Massachusetts.